Monaco Asset Management SAM Acquires New Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Monaco Asset Management SAM purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 40,000 shares of the company's stock, valued at approximately $423,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of ROIV. Swiss National Bank grew its stake in shares of Roivant Sciences by 8.1% in the fourth quarter. Swiss National Bank now owns 546,746 shares of the company's stock valued at $6,140,000 after buying an additional 41,000 shares in the last quarter. Natixis Advisors L.P. acquired a new stake in Roivant Sciences in the fourth quarter valued at approximately $699,000. Charles Schwab Investment Management Inc. lifted its position in shares of Roivant Sciences by 5.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,023,027 shares of the company's stock worth $22,719,000 after purchasing an additional 99,148 shares in the last quarter. First Turn Management LLC purchased a new position in shares of Roivant Sciences in the fourth quarter valued at $15,312,000. Finally, Vanguard Personalized Indexing Management LLC increased its stake in Roivant Sciences by 26.7% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 18,742 shares of the company's stock worth $210,000 after buying an additional 3,955 shares during the period. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV traded down $0.31 on Tuesday, reaching $12.19. 7,547,592 shares of the company's stock were exchanged, compared to its average volume of 5,713,143. Roivant Sciences Ltd. has a fifty-two week low of $8.24 and a fifty-two week high of $13.24. The business's 50-day moving average is $11.24 and its two-hundred day moving average is $11.02. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $9.01 billion, a price-to-earnings ratio of 2.42 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The firm had revenue of $55.10 million for the quarter, compared to analyst estimates of $30.72 million. During the same quarter in the prior year, the business earned ($0.38) earnings per share. Roivant Sciences's quarterly revenue was up 155.1% on a year-over-year basis. As a group, equities research analysts forecast that Roivant Sciences Ltd. will post -1.14 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research report on Monday. Piper Sandler lifted their price objective on Roivant Sciences from $20.00 to $22.00 and gave the stock an "overweight" rating in a report on Wednesday, July 10th. Finally, HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Monday, August 19th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Roivant Sciences presently has an average rating of "Moderate Buy" and an average price target of $17.10.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.